The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review

Frontiers in Medicine

article

Lei Zhang¹  Ke Pu⁴  Xiaojun Liu⁶  Sarah Da Won Bae⁷  Romario Nguyen⁷  Suyang Bai⁴  Yi Li⁴  Liang Qiao⁷ 

[1] The First Clinical Medical College, Lanzhou University;Department of General Surgery, The First Hospital of Lanzhou University;Key Laboratory of Biological Therapy and Regenerative Medicine Transformation Gansu Province;Department of Gastroenterology, The First Hospital of Lanzhou University;Key Laboratory for Gastrointestinal Diseases of Gansu Province, Lanzhou University;Department of Medical Oncology, The First Hospital of Lanzhou University;Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Clinical School

关键词: HLCs;    primary human hepatocytes;    liver disease;    clinical application;    IPS cell;   

DOI  :  10.3389/fmed.2021.644594

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Liver diseases are a major health concern globally, and are associated with poor survival and prognosis of patients. This creates the need for patients to accept the main alternative treatment of liver transplantation to prevent progression to end-stage liver disease. Investigation of the molecular mechanisms underpinning complex liver diseases and their pathology is an emerging goal of stem cell scope. Human induced pluripotent stem cells (hiPSCs) derived from somatic cells are a promising alternative approach to the treatment of liver disease, and a prospective model for studying complex liver diseases. Here, we review hiPSC technology of cell reprogramming and differentiation, and discuss the potential application of hiPSC-derived liver cells, such as hepatocytes and cholangiocytes, in refractory liver-disease modeling and treatment, and drug screening and toxicity testing. We also consider hiPSC safety in clinical applications, based on genomic and epigenetic alterations, tumorigenicity, and immunogenicity.

【 授权许可】

CC BY